MedPath

Evaluation of the Enoxaparin in the Prophylaxis of Deep Venous Thrombosis

Phase 2
Conditions
Deep vein thrombosi.
Other venous embolism and thrombosis
Registration Number
IRCT20130917014693N11
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Age between 18 and 65 years old
Padua risk score = 4 points
Signing the informed consent form

Exclusion Criteria

Patients in shock state
Acute kidney injury
Chronic kidney injury
History of hemorrhage in past one month
Invasive surgical procedures which needs to enoxaparin discontinuation
Pregnancy
Lactation
Thrombophilia
Antithrombin deficiency
Previous history of venous thrombosis
Body mass index more than 35 kg/m2
Platelet less than 50000 cells/uL

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The activity level of anti factor Xa. Timepoint: Three hours after third doses. Method of measurement: Chromogenic assay.
Secondary Outcome Measures
NameTimeMethod
Occurance rate of deep vein thrombosis. Timepoint: Daily. Method of measurement: Clinical examination and sonography is necessary cases.;Occurrence rate of adverse drug reactions. Timepoint: Daily. Method of measurement: Observation.
© Copyright 2025. All Rights Reserved by MedPath